Business Wire

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Shionogi Inc., a New Jersey-based ...
News Medical

Could neutralizing SARS-CoV-2 monoclonal antibodies pre-exposure prophylaxis be cost-effective in a population at risk for severe COVID-19?

A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...
clinicaladvisor.com

Long-Acting Injectable Pre-Exposure Prophylaxis for Reducing Risk of Contracting HIV-1

HIV-1 infection remains a major public health problem, with an estimated 38.4 million people living with HIV and 1.5 million new HIV infections reported worldwide in 2021. The risk of HIV infection ...